We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Kohl Continues Investigation Into Avastin Availability
Kohl Continues Investigation Into Avastin Availability
November 30, 2007
Senate Special Committee on Aging Chairman Herb Kohl (D-Wis.) is continuing his investigation into Genentech’s decision to limit the availability of cancer drug Avastin, questioning company officials on their decision and asking the FDA’s opinion on the move.